Alterations in amphetamine-stimulated dopamine overflow due to the Nurr1-null heterozygous genotype and postweaning isolation.
The nuclear receptor Nurr1 functions to regulate dopamine neurotransmission, as Nurr1-null heterozygous (+/-) mice have alterations in dopamine function and, when raised in isolation immediately after weaning, have disruptions in sensorimotor gaiting, a behavior altered in schizophrenia and modulated by dopamine neurotransmission. The goal of this study was to determine nigrostriatal and mesoaccumbens dopamine neurotransmission using microdialysis in +/- and wild-type (+/+) mice raised in groups or isolation. In the striatum, isolation significantly reduced amphetamine-stimulated dopamine overflow and levels of the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC). The +/- genotype alone caused a small, nonsignificant reduction in basal dopamine levels but a significant reduction in basal DOPAC levels. In the nucleus accumbens shell, the +/- genotype elevated basal dopamine levels. Isolation had genotype specific effects, causing an elevation in amphetamine-stimulated dopamine overflow in +/- mice but a reduction in +/+ mice, resulting in a large difference in stimulated dopamine overflow when comparing the +/+ and +/- isolated mice. These data indicate that a deletion of a single allele of Nurr1, which produces only subtle changes alone, when coupled with a developmental stressor, can dramatically alter mesoaccumbens dopamine neurotransmission. These observations demonstrate how the combination of genetic predisposition and an environmental insult during development can cause dysfunction of dopamine neurotransmission and could contribute to diseases such as schizophrenia or attention deficit hyperactivity disorder.
Moore
Talisha M
TM
Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi 39762, USA.
Brown
Timothy
T
Cade
Mirae
M
Eells
Jeffrey B
JB
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D004298:Dopamine / Q000235:genetics / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006580:Genetic Carrier Screening / Q000379:methods; D005838:Genotype; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D012934:Social Isolation / Q000523:psychology; D014157:Transcription Factors / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D014886:Weaning
D004268:DNA-Binding Proteins; C539883:Nr4a2 protein, mouse; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D014157:Transcription Factors; D000661:Amphetamine; D004298:Dopamine